Flamel Technologies' NDA for Bloxiverz gets FDA nod

06/4/2013 | RTT News

The FDA has granted Flamel Technologies approval for its new drug application for Bloxiverz. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents following surgery.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT